Epidemiology of Morbidity and Mortality of COVID-19 Patients During the Period of June 2020-September 2021 in Sulianti Saroso Infectious Disease Hospital, Indonesia

Overview

Journal Malays J Med Sci

Specialty General Medicine

Date 2024 Oct 17

PMID 39416744

Authors

Pompini Agustina Sitompul

Nina Mariana

Siti Maemun

Aninda Dinar Widiantari

Farida Murtiani

Rosamarlina Rosamarlina

Adria Rusli

Titi Sundari

Tri Bayu Purnama

Affiliations

Soon will be listed here.

Abstract

Objectives: The increasing mortality rate of COVID-19 has remained an international public health concern. Limited studies on clinical treatment and morbidity in hospital settings are available in Indonesia. This present study aims to analyse demographic characteristics, clinical signs and treatment in COVID-19 patients and their association to the mortality case in Sulianti Saroso Infectious Disease Hospital.

Methods: The study applied a retrospective cohort approach to all COVID-19 inpatients confirmed by polymerase chain reaction (PCR) testing in Sulianti Saroso Infectious Disease Hospital from 1 June 2020 to 30 September 2021. Overall survival rates until the end of the study were calculated using the Kaplan-Meier method and compared using the log-rank test. A Cox regression model was used to evaluate the crude and adjusted hazard ratios for associated factors.

Results: We collected 1,970 inpatient data that met our inclusion and exclusion criteria. Most of them were 19 years old-59 years old (73.2%) and male (52.6%), and 966 (49%) patients had comorbidities. Approximately 63.9%, 89.2%, 89.8%, 82%, and 14.1% of the patients had ferritin levels ≤ 800, received antiviral treatment, were treated in non-intensive wards, had a moderate or mild clinical stage and did not survive, respectively. In the adjusted analysis, mortality was associated with sex (hazard ratio [HR]: 1.12; 95% CI: 1.02, 1.23), presence of comorbidity (HR: 1.19; 95% CI: 1.08, 1.30) and favipiravir (FPV) plus azithromycin treatment (HR: 1.21; 95% CI: 1.06,1.39). FPV treatment (HR: 1.35; 95% CI: 1.04, 1.75) was associated with higher mortality.

Conclusion: Tailored approaches to treatment, considering individual risk factors and comorbidities, are crucial in improving patient outcomes.

References

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

. SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(50):1731-1734. PMC: 8675659. DOI: 10.15585/mmwr.mm7050e1. View

Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo Jr C, Liang L . Association of asthma and its genetic predisposition with the risk of severe COVID-19. J Allergy Clin Immunol. 2020; 146(2):327-329.e4. PMC: 7423602. DOI: 10.1016/j.jaci.2020.06.001. View

Xu J, Yang X, Yang L, Zou X, Wang Y, Wu Y . Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China. Crit Care. 2020; 24(1):394. PMC: 7336107. DOI: 10.1186/s13054-020-03098-9. View

Tian W, Jiang W, Yao J, Nicholson C, Li R, Sigurslid H . Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. J Med Virol. 2020; 92(10):1875-1883. PMC: 7280666. DOI: 10.1002/jmv.26050. View

Ruan Q, Yang K, Wang W, Jiang L, Song J . Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020; 46(5):846-848. PMC: 7080116. DOI: 10.1007/s00134-020-05991-x. View

Sayah W, Berkane I, Guermache I, Sabri M, Lakhal F, Rahali S . Interleukin-6, procalcitonin and neutrophil-to-lymphocyte ratio: Potential immune-inflammatory parameters to identify severe and fatal forms of COVID-19. Cytokine. 2021; 141:155428. PMC: 7834734. DOI: 10.1016/j.cyto.2021.155428. View

Bozkurt F, Tercan M, Patmano G, Bingol Tanriverdi T, Demir H, Yurekli U . Can Ferritin Levels Predict the Severity of Illness in Patients With COVID-19?. Cureus. 2021; 13(1):e12832. PMC: 7899245. DOI: 10.7759/cureus.12832. View

Setiadi W, Rozi I, Safari D, Daningrat W, Johar E, Yohan B . Prevalence and epidemiological characteristics of COVID-19 after one year of pandemic in Jakarta and neighbouring areas, Indonesia: A single center study. PLoS One. 2022; 17(5):e0268241. PMC: 9098020. DOI: 10.1371/journal.pone.0268241. View

10.

Kim D, Choe Y, Jeong J . Understanding and Interpretation of Case Fatality Rate of Coronavirus Disease 2019. J Korean Med Sci. 2020; 35(12):e137. PMC: 7105506. DOI: 10.3346/jkms.2020.35.e137. View

11.

Liu S, Wang X, She F, Zhang W, Liu H, Zhao X . Effects of Neutrophil-to-Lymphocyte Ratio Combined With Interleukin-6 in Predicting 28-Day Mortality in Patients With Sepsis. Front Immunol. 2021; 12:639735. PMC: 8007868. DOI: 10.3389/fimmu.2021.639735. View

12.

Kang S, Jung S . Age-Related Morbidity and Mortality among Patients with COVID-19. Infect Chemother. 2020; 52(2):154-164. PMC: 7335648. DOI: 10.3947/ic.2020.52.2.154. View

13.

Khalili M, Karamouzian M, Nasiri N, Javadi S, Mirzazadeh A, Sharifi H . Epidemiological characteristics of COVID-19: a systematic review and meta-analysis. Epidemiol Infect. 2020; 148:e130. PMC: 7343974. DOI: 10.1017/S0950268820001430. View

14.

Tartof S, Qian L, Hong V, Wei R, Nadjafi R, Fischer H . Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization. Ann Intern Med. 2020; 173(10):773-781. PMC: 7429998. DOI: 10.7326/M20-3742. View

15.

Surendra H, Elyazar I, Djaafara B, Ekawati L, Saraswati K, Adrian V . Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. Lancet Reg Health West Pac. 2021; 9:100108. PMC: 7924904. DOI: 10.1016/j.lanwpc.2021.100108. View

16.

Ucan A, Cerci P, Efe S, Akgun H, Ozmen A, Yagmuroglu A . Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case-control study. Virol J. 2021; 18(1):102. PMC: 8148395. DOI: 10.1186/s12985-021-01577-1. View

17.

Bhaskaran K, Rentsch C, Mackenna B, Schultze A, Mehrkar A, Bates C . HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV. 2020; 8(1):e24-e32. PMC: 7773630. DOI: 10.1016/S2352-3018(20)30305-2. View

18.

Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J . Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. Front Pharmacol. 2021; 12:683296. PMC: 8443786. DOI: 10.3389/fphar.2021.683296. View

19.

Tadmor T, Welslau M, Hus I . A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia. Expert Rev Hematol. 2017; 11(1):57-70. DOI: 10.1080/17474086.2018.1407645. View

20.

Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P . Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med. 2020; 2(8):1069-1076. PMC: 7314621. DOI: 10.1007/s42399-020-00363-4. View